Derek Meisner - Jan 19, 2024 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Signature
/s/ Derek Meisner
Stock symbol
ABOS
Transactions as of
Jan 19, 2024
Transactions value $
-$31,048
Form type
4
Date filed
1/19/2024, 07:06 PM
Previous filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Sale -$31K -8.93K -7.58% $3.48 109K Jan 19, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the Reporting Person in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.4000 to $3.6500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.